Breyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectie

{
  "form": "Suspensie voor injectie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/breyanzi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lisocabtagene Maraleucel",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126986",
  "excipients": [
    "ADENOSINE",
    "CALCIUMCHLORIDE 2-WATER (E 509)",
    "CAPRYLZUUR (E 570)",
    "DEXTRAAN 40",
    "DIMETHYLSULFOXIDE",
    "GLUCOSE 0-WATER",
    "GLUTATHION (L-)",
    "HUMAAN ALBUMINE",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "KALIUMHYDROXIDE (E 525)",
    "KALIUMWATERSTOFCARBONAAT (E 501 (II))",
    "LACTOBIONZUUR",
    "MAGNESIUMCHLORIDE 6-WATER (E 511)",
    "MANNITOL (D-) (E 421)",
    "N-2-HYDROXYETHYLPIPERAZINE-N'-2-ETHAANSULFONZUUR",
    "N-ACETYL-D,L-TRYPTOFAAN",
    "NATRIUMACETAAT 3-WATER (E 262)",
    "NATRIUMCHLORIDE",
    "NATRIUMGLUCONAAT (E 576)",
    "NATRIUMHYDROXIDE (E 524)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "LISOCABTAGEEN MARALEUCEL (CD4+ component)"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/04/04",
  "procedure_number": "EMEA/H/C/004731",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1631",
  "additional_monitoring": "Y"
}